Following these transactions, Dierks no longer holds shares in the company. Harmony (JO:) Biosciences, which maintains an excellent financial health score according to InvestPro data, holds more cash than debt on its balance sheet and demonstrates strong liquidity with a quick ratio of 3.24. The pharmaceutical company continues to focus on the development and commercialization of innovative therapies for patients with rare neurological diseases.
Following these transactions, Dierks no longer holds shares in the company. Harmony Biosciences, which maintains an excellent financial health score according to InvestPro data, holds more cash than debt on its balance sheet and demonstrates strong liquidity with a quick ratio of 3.24. The pharmaceutical company continues to focus on the development and commercialization of innovative therapies for patients with rare neurological diseases.
Following these transactions, Dierks no longer holds shares in the company. Harmony Biosciences, which maintains an excellent financial health score according to InvestPro data, holds more cash than debt on its balance sheet and demonstrates strong liquidity with a quick ratio of 3.24. The pharmaceutical company continues to focus on the development and commercialization of innovative therapies for patients with rare neurological diseases.
In other recent news, Harmony Biosciences reported robust fourth-quarter 2024 earnings, with revenue reaching approximately $201 million, matching HC Wainwright’s forecast and slightly above consensus of $712 million. The company also projects revenue of approximately $714 million for the full year 2024. Looking ahead, Harmony released a revenue forecast for 2025, estimating between $820 million and $860 million.
In addition to its financial performance, Harmony Biosciences has made significant progress in its product portfolio. The company is awaiting a decision from the FDA on a supplemental new drug application for WAKIX, its lead product, for the treatment of idiopathic hypersomnia, expected in the first quarter of 2025. Further developments are expected, including the launch potential for a first study in humans. studies of BP1.15205, an OX2R agonist, in third quarter 2025, and topline data from a pivotal phase 3 trial evaluating ZYN002 in Fragile X syndrome by third quarter 2025.
Analysts at HC Wainwright and Oppenheimer reaffirmed their confidence in the company, maintaining a buy rating and an outperform rating, respectively. The former has a $75.00 price target for the company’s stock, while the latter increased his price target from $59 to $61. These ratings reflect analysts’ anticipation of Harmony Biosciences’ continued momentum and growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information, consult our General Terms and Conditions.